![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Biogen Will Settle for $22 Million Over Alleged Drugs Kickback Scheme
Biogen Will Settle for $22 Million Over Alleged Drugs Kickback Scheme
December 22, 2020
Biogen has agreed to a $22 million settlement to resolve allegations that donations it made to charities were kickbacks to Medicare patients for out-of-pocket costs associated with its multiple sclerosis medications.
According to the Department of Justice, Biogen together with specialty pharmacy Advanced Care Scripts made payments to two charities to cover co-pays for Medicare patients for Avonex (interferon beta-1a) and Tysabri (natalizumab).
“By treating the foundations simply as conduits to pay the co-pays of its own patients, Biogen violated the anti-kickback statute and undermined Medicare’s co-pay structure, which Congress intended as a safeguard against inflated drug prices,” said U.S. Attorney Nathaniel R. Mendell.
Upcoming Events
-
21Oct